Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy for head and neck cancer: Present and future.
Fasano M, Corte CMD, Liello RD, Viscardi G, Sparano F, Iacovino ML, Paragliola F, Piccolo A, Napolitano S, Martini G, Morgillo F, Cappabianca S, Ciardiello F. Fasano M, et al. Among authors: piccolo a. Crit Rev Oncol Hematol. 2022 Jun;174:103679. doi: 10.1016/j.critrevonc.2022.103679. Epub 2022 Apr 6. Crit Rev Oncol Hematol. 2022. PMID: 35395371 Free article. Review.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.
Diana A, Carlino F, Buono G, Antoniol G, Famiglietti V, De Angelis C, Carrano S, Piccolo A, De Vita F, Ciardiello F, Daniele B, Arpino G, Orditura M. Diana A, et al. Among authors: piccolo a. Front Oncol. 2022 Mar 28;12:813462. doi: 10.3389/fonc.2022.813462. eCollection 2022. Front Oncol. 2022. PMID: 35419293 Free PMC article.
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.
Carlino F, Diana A, Ventriglia A, Piccolo A, Mocerino C, Riccardi F, Bilancia D, Giotta F, Antoniol G, Famiglietti V, Feliciano S, Cangiano R, Lobianco L, Pellegrino B, De Vita F, Ciardiello F, Orditura M. Carlino F, et al. Among authors: piccolo a. Cancers (Basel). 2022 Oct 11;14(20):4981. doi: 10.3390/cancers14204981. Cancers (Basel). 2022. PMID: 36291765 Free PMC article.